- freely available
Int. J. Mol. Sci. 2010, 11(7), 2746-2758; doi:10.3390/ijms11072746
Published: 16 July 2010
Abstract: Platycodon grandiflorum (Campanulaceae) is used as traditional medicine in Asian countries. In Korean traditional medicine, Platycodon root has been widely used since ancient times as a traditional drug to treat cold, cough and asthma. However, its effects on bone marrow-derived mast cell (BMMC)-mediated allergy and inflammation mechanisms remain unknown. In this study, the biological effect of Platycodon root ethanol extract (PE) was evaluated in BMMC after induction of allergic mediators by phorbol 12-myristate 13-acetate (PMA) plus calcium ionophore A23187 (A23187) stimulation. The effect of PE on the production of several allergic mediators, such as interleukin-6 (IL-6), prostaglandin D2 (PGD2), leukotriene C4 (LTC4), β-Hexosaminidase (β-Hex) and cyclooxygenase-2 (COX-2) protein, was investigated. The results demonstrate that PE inhibits PMA + A23187 induced production of IL-6, PGD2, LTC4, β-Hexosaminidase and COX-2 protein. Taken together, these results indicate that PE has the potential for use in the treatment of allergy.
Platycodon root is the root of Platycodon grandiflorum, which belong to the family of Campanulaceae. In Asian countries, Platycodon root has been widely used since ancient times as a traditional drug. More specifically, it is often prescribed as a folk remedy and herbal medicine for coughs, sputum, asthma and tonsillitis disorder effects. Recent studies have shown that materials derived from Platycodon root are effective against asthma, have anti-inflammatory effects and act against fatty liver [1–3].
Mast cells are one of the most important cells for diseases related to allergic. When activated, mast cells release a number of biologically active molecules through various processes. Histamine, serotonin and serine proteases are released through exocytosis, lipid mediators such as eicosanoids are released through the activation of the cyclooxygenase-2 and 5-lipoxygenase (LOX) pathways and various cytokines are synthesized de novo [4–6]. They have long been implicated in the pathology and mortality of anaphylaxis and other allergic disorders by virtue of both their ability to be activated through FcɛRI-bound antigen-specific IgE and their concentration at surfaces that interface with the external environment . Mast cells may also be activated by various cytokines through cytokine receptors. Activation through any of these cytokine receptors leads to release of a number of biologically active molecules, including histamine, serotonin, proteoglycans and neutral proteases. Among these molecules, histamine is one of the most important chemical mediators in the pathologic allergic reaction .
Interleukin-6 (IL-6) is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation [8,9]. Further, IL-6 modulates a variety of physiological events on the nervous system, endocrine system and bone metabolism [9,10].
Cyclooxygenase (COX) is a bi-functional enzyme that first catalyzes the addition of two molecules of oxygen to arachidonic acid to form the hydroperoxide prostaglandin G2 (PGG2), then reduces the hydroperoxide to the alcohol, PGH2, by a peroxidase activity . It has two isoforms, COX-1 and COX-2. COX-1, which is constitutively expressed in most cells, is responsible for the production of prostaglandins that maintain homeostasis. In contrast, COX-2 is upregulated in inflammatory cells in response to an inflammatory stimulus and is responsible for the production of prostaglandins at the site of inflammation [12–15]. Therefore, there is an increasing interest in the use of COX-2 inhibitors.
In the present study, the ability of Platycodon root ethanol extract (PE) to suppress phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 (A23187)-induced IL-6, PGD2, LTC4 production and COX-2 protein expression in BMMC was investigated. The results show that PE has anti-allergic activity.
2. Results and Discussion
2.1. The Effects of PE on BMMC Viability
Allergy is a disorder of the immune system often also referred to as atopy. Allergic reactions occur to normally harmless environmental substances known as allergens; these reactions are acquired, predictable, and rapid. Strictly, allergy is one of four forms of hypersensitivity and is called type I hypersensitivity. It is characterized by excessive activation of mast cells and basophils by a type of antibody known as IgE, resulting in an extreme inflammatory response . The cytotoxic effect of PE was evaluated in BMMC by MTS assay (see Section 3). Figure 1 shows that treatment with PE at concentrations of up to 1000 μg/mL did not affect the viability of BMMC.
2.2. The Effects of PE on PMA and A23187-Induced IL-6 Secretion
IL-6 is released in a coordinated network and plays an important role in chronic disease. As such, the pattern of cytokine expression largely determines the nature and persistence of the inflammatory response . IL-6 is a potent mediator of inflammatory processes, and a pleiotropic inflammatory cytokine produced by T cells, macrophages, monocytes, and synovial fibroblasts. To evaluate the effect of PE on the production of IL-6, we pretreated cells with PE (100 or 1000 μg/mL) before stimulation with PMA (50 nM) and A23187 (1 μM) for 6 h, followed by analysis using ELISA. As shown in Figure 2, the level of IL-6 considerably increased after stimulation with PMA plus A23187 in BMMC. Pretreatment of cells with PE (100 or 1000 μg/mL) inhibited these increases in a concentration-dependent and statistically significant manner.
2.3. The Effects of PE on PMA and A23187-Induced PGD2 Production
BMMC exhibit biphasic PGD2 biosynthetic responses over time, in addition to COX-1-dependent immediate and COX-2-dependent delayed responses . The immediate PGD2 generation occurring within 2 h is associated with the coupling of COX-,1 and the delayed PGD2 generation, which occurs after several hours of culturing (between 2–10 h), is associated with the de novo induction and function of COX-2 after stimulation with particular stimuli . This cell model also appears to be suitable for assessing the effect of 5-LOX inhibitors, since the immediate LTC4 generation elicited by the IgE-dependent or cytokine-initiated stimulus occurs in BMMC through 5-LOX . Therefore, the BMMC system is useful for screening selective COX-1/COX-2 or 5-LOX and COX-2/5-LOX dual inhibitors from various sources [20,21]. After stimulation with PMA + A23187, cell-cultured mediums were harvested to measure the level of PGD2 production. PGD2 production was clearly detected 2 h after stimulation with PMA + A23187. PGD2 production also peaked in PMA (50 nM) + A23187 (1 μM). Next, an investigation of the inhibitory effect of PE on the PMA + A23187 induced PGD2 production in BMMC was performed. Figure 3 shows PE significantly inhibited PMA plus A23187-induced PGD2 production in dose-dependent manner. These results show that PE can inhibit PMA plus A23187 induced PGD2 production in BMMC.
2.4. The effects of PE on PMA and A23187-Induced LTC4 Production
Arachidonic acid can also be converted to leukotrienes (LTs) by the action 5-lipoxygenase (LOX) in BMMC. The inhibition of 5-LOX is believed to be the ideal treatment for allergic diseases and asthma . Therefore, the inhibitory activity of PE on the generation of LTC4 in the BMMC was examined. Figure 4 shows that the BMMC stimulated with PMA + A23187 for 15 min produced approximately 2.3 ng/mL LTC4, and preincubation of the BMMC with PE resulted in the dose-dependent suppression of this LTC4 biosynthesis. After stimulation with PMA plus A23187, cell-cultured mediums were harvested to measure the level of LTC4 production. LTC4 production was clearly detected 15 min after stimulation with PMA + A23187. LTC4 production also peaked in PMA (50 nM) plus A23187 (1 μM). Next, an investigation of the inhibitory effect of PE on the PMA and A23187 induced LTC4 production in BMMC was performed. Figure 4 shows PE significantly inhibited PMA plus A23187-induced LTC4 production in dose-dependent manner. These results show that PE can inhibit PMA + A23187 induced LTC4 production in BMMC.
2.5. The Effects of PE on PMA and A23187-Induced COX-2 Protein Expression
COX-2 is strongly induced in various activated cells. It has been reported that PGD2, which is the COX-2 metabolite released from activated mast cells, is also essential for the pathogenesis of eosinophilic airway . The inhibitory effect of the PE on PGD2 production was examined to determine if it is a direct effect of the COX-2 protein or if this inhibition is mediated by some other mechanism. Western blot analysis was performed to determine if the inhibitory effect of PE on PGs were related to modulation of the COX-2 protein expression. As shown in Figure 5, the COX-2 protein was not detected in unstimulated BMMC. However, in response to PMA plus A23187, COX-2 protein was strongly expressed, and COX-2 protein expression was inhibited in a dose-dependent manner by PE.
2.6. The Inhibitory Effects of PE on PMA and A23187-Induced Degranulation
When mast cells are activated by various stimuli, the release of histamine bears a close parallel to that of β-Hex, which is one degranulation marker . An investigation of the effect of PE on the PMA p+ A23187-induced β-Hex release was performed using ELISA. As shown in Figure 6, pretreatment of BMMC with PE at concentrations of 100 or 1000 μg/mL reduced β-Hex production.
2.7. High Performance Liquid Chromatography (HPLC)
HPLC analysis of saponins from Platycodon root was carried out on a Hitachi L-6200 instrument equipped with an evaporative light scattering detection (ELSD) system and SIL-9A auto injector (Shimadzu, Japan). A Zorbax SB-Aq C18 column (150 × 4.6 mm, 5 μm particle size) from Agilent Technologies (Palo Alto, CA, USA) was used for all separations. HPLC conditions were as follows: eluent A, water; eluent B, acetonitrile; gradient, 0–6 min (10–15% B), 6–50 min (15–25% B), 50–60 min (25–47.5% B), and then equilibrated with 10% B for 8 min at a flow of 1 mL/min. The ELSD was set to a probe temperature of 70 °C, a gain of 7 and the nebulizer gas nitrogen adjusted to 2.5 bar. As shown in Figure 7, peaks were assigned by comparing their retention times with that of each reference compound eluted in parallel with a series of mobile phase and by spiking sample with reference compounds. The standard solutions containing 2–400 μg/mL corresponding to test ranges of 10 saponins were prepared in triplicate and 50 μL of each sample was injected into the HPLC column for the construction of calibration curves and linear ranges. The calibration curves were plotted by the peak area versus concentration of each analyte. The linearity was evaluated by linear regression analysis calculated by the least square regression method.
The samples used in the previous experiment was purchased at a local herbal market and originated from China. In addition, the sample was extracted with 100% methanol . In this experiment, the roots were collected in Korea and were extracted with 70% ethanol. These differences between the samples might affect the variation of saponin composition (Table 1).
3. Experimental Section
3.1. Plant Materials
Platycodon roots were collected from JinAn, Korea, in February, 2009. They were identified by Dr. D.Y. Kwon. A voucher specimen was deposited in the Laboratory of Herbalogy, College of Pharmacy, Wonkwang University, Iksan, Korea. The dried aerial parts of the Platycodon roots (1 kg) were cut into small pieces and extracted repeatedly with 70% ethanol. The solution was filtered and evaporated in vacuo to yield a powered extract (177.4 g).
Male Balb/cJ mice (20–30 g) were purchased from DAMUL, Korea. All animals were kept in a temperature controlled room under a 12 h light/12 h dark cycle. The animals were provided with free access to commercial solid food (SCF Co., Ltd. Korea) and water ad libitum. Mice were acclimatized for at least one week prior to beginning the experiments.
3.3. Drugs and Chemicals
RPMI 1640, penicillin and streptomycin and FBS (Fetal Bovine Serum) were obtained from Hyclone (Hyclone Labs Logan, UT). Bovine serum albumin (BSA), PMA and A23187 were purchased from Sigma (St. Louis, MO, USA). COX-2 and β-actin monoclonal antibodies and peroxidase conjugated secondary antibody were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
3.4. Preparation and Activation of Bone Marrow-Derived Mast Cells (BMMC)
Bone marrow mast cells from male Balb/cJ mice were cultured for up to 10 weeks in 50% enriched medium (RPMI 1640 containing 2 mM L-glutamine, 0.1 mM nonessential amino acids, antibiotics, and 10% fetal bovine serum) and 50% WEHI-3 cell-conditioned medium as a source of IL-3. After 3 weeks, >98% of the cells were BMMC.
3.5. MTS Assay for Cell Viability
The cell viability was examined by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Briefly, BMMC were seeded at a density of 5 × 105 cells/mL in 96 well plates (Nunc, Denmark). Each batch of cells included a non-treated group as control. PE (100 or 1000 μg/mL) was then added to each well, after which the plates were incubated for 24 h at 37 °C under 5% CO2. Next, MTS solutions (5 mg/mL) were added to each well. Next, the optical density was read at 490 nm. The cytotoxicity was then calculated by subtracting the ratio of the mean absorbance value for treated cells over the mean absorbance value for untreated cells from one.
3.6. Enzyme-Linked Immunosorbent Assay (ELISA)
Cells were seeded at a density of 1 × 106 cells/mL in 24 well tissue culture plates and then pretreated with various concentrations of PE (100 or 1000 μg/mL) for 30 min prior to PMA (50 nM) plus A23187 (1 μM) stimulation. ELISA plates (Falcon, Becton Dickinson Labware) were then coated overnight at 4 °C with anti-mouse IL-6 antibody diluted in coating buffer (0.1 M carbonate, pH 9.5) and then washed three times with PBS containing 0.05% tween 20. Non-specific protein binding sites were then blocked by incubating the plates with assay diluent (PBS containing 10% FBS, pH 7.0) for at least 1 hour. Immediately following the incubation, each sample and IL-6 standard were added to the wells, after which the plates were incubated for 2 h. Next, working detector (biotinylated anti-mouse IL-6 monoclonal antibody and streptavidin-HRP reagent) was added to each well and the plates were incubated for an additional 1 h. Finally, substrate solution (tetramethylbenzidine: TMB) was added to the wells, after which the plates were then incubated in the dark for 30 min. Next, the reaction was stopped using stop solution (2NH3PO4) and the absorbance at 450 nm was then measured. All standards and samples were assayed in duplicate.
3.7. Determination of Prostaglandin D2 (PGD2) Levels
To measure the inhibitory activity of PE on COX-2, cells were suspended in enriched medium at 1 × 106 cells/mL and preincubated with aspirin (10 g/mL) for 2 h to irreversibly inactivate any pre-existing COX-1. After washing, the BMMC were activated with PMA (50 nM) + A23187 (1 μM) at 37 °C for 2 h in the presence or absence of PE dissolved in PBS. All reactions were quenched by centrifugation at 890 g at 4 °C for 5 min. The supernatant and cell pellet were frozen immediately in liquid N2 and stored at −80 °C until needed for further analysis. Under these conditions, the COX-2-dependent phase of PGD2 generation reached 1.3 ng/106 cells. The data are reported as the arithmetic mean of triplicate determinations.
3.8. Determination of Leukotriene C4 (LTC4) Levels
BMMC suspended in enriched medium at 1 × 106 cells/mL were pretreated with PE for 30 min at 37 °C and stimulated with PMA (50 nM) + A23187 (1 μM). After 15 min of stimulation, the supernatants were isolated for further analysis by enzyme immunoassay (EIA). LTC4 was determined using an EIA kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions. Under the conditions employed, LTC4 reached 2.3 ng/106 cells. All data are the arithmetic means of triplicate determinations.
3.9. Western Blot Analysis
After activation with PMA (50 nM) + A23187 (1 μM), BMMC were washed once with 10 mM phosphate buffer (pH 7.4) containing 150 mM NaCl (PBS) and lysed in PBS containing 0.1% SDS and 10 mM β-mercaptoethanol at 1 × 107 cells/mL. The lysate (1 × 105 cells equivalent) was applied to 10% SDS-polyacrylamide gels. After running the gel, the protein bands were blotted onto nitrocellulose membranes (Schleicher and Schull, Dassel, Germany) using a semi-dry blotter (MilliBlot-SDE system, Millipore, Bedford, MA, USA) according to the manufacturer’s instructions. Membranes were then washed once with 10 mM Tris-buffered saline (TBS, pH 7.2) containing 0.1% tween-20 (TBS-T), and then blocked for 1 h in TBS-T containing 3% skim milk. After washing the membranes with TBS-T, an antibody directed against COX-2 was added at a dilution of 1:5000 in TBS-T. After incubation for 2 h followed by washing three times, membranes were treated for 1 h with horseradish peroxide-conjugated goat anti-rabbit IgG (Santa Cruz, CA, USA) (diluted to 1:7000) in TBS-T. The protein bands were visualized using an enhanced chemiluminesence (ECL) system (Amersham Corp., Newark, NJ, USA).
3.10. Assay of β-Hexosaminidase Release
β-Hexosaminidase (β-Hex), a marker of mast cell degranulation, was quantitated by spectrophotometric analysis of p-nitrophenyl-2-acetamido-2-deoxy-β-D-glucopyranoside hydrolysis (Sigma, St. Louis, MO, USA). Briefly, after harvesting the supernatant, cells were lysed in the same volume of medium by three freeze/thaw cycles. Ten milliliters of the BMMC lysate or supernatant samples were mixed with 50 μL of β-Hex substrate solution (1.3 mg/mL p-nitrophenyl-2-acetamido-2-deoxy-β-D-glucopyranoside in 100 mM sodium citrate, pH 4.5) in the wells of 96-well plate and then incubated at 37 °C for 90 min. The reaction was stopped by adding 140 μL of 0.2 M glycine-NaOH (pH 10.7). Absorbance was measured at 410 nm in a microplate reader. The percentage of β-Hex released into the supernatant was calculated by the following formula: [S/(S + P)] × 100, where S and P are the β-Hex contents of the supernatant and cell pellet, respectively.
The chromatographic system consisted of a pump (Shimadzu LC-10AT VP) and a UV detector (Shimadzu LC-SPD-10A VP). A Shim-pack VP-ODS column (4.6 × 250 mm, Shimadzu) was used. An isocratic of CH3CN:CH3OH:H2O (11:11:8) was used as the mobile phase at a flow rate of 1.0 mL/min. The HPLC was monitored at 254 nm.
3.12. Statistical Analysis
The data from the experiments are presented as the mean ± S.E.M. The level of statistical significance was determined by analysis of variance (ANOVA) followed by Dunnett’s t-test for multiple comparisons. P values less than 0.05 were considered to be significant.
The conclusion of these investigations is that PE can exhibit inhibitory effects on PMA and A23187-induced IL-6, PGD2, LTC4 production and COX-2 protein expression in bone marrow-derived mast cells. Considering the results, PE could represent a new drug treatment for various allergic diseases. Therefore, further studies are necessary to examine its clinical application.
This research was supported by a grant from the Jinan Eco-Red Ginseng Oriental Medicine Industry Cluster Agency.
- Choi, JH; Hwang, YP; Lee, HS; Jeong, HG. Inhibitory effect of Platycodi Radix on ovalbumin-induced airway inflammation in a murine model of asthma. Food Chem. Toxicol 2009, 47, 1272–1279.
- Ahn, KS; Noh, EJ; Zhao, HL; Jung, SH; Kang, SS; Kim, YS. Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci 2005, 76, 2315–2328.
- Khanal, T; Choi, JH; Hwang, YP; Chung, YC; Jeong, HG. Protective effects of saponins from the root of Platycodon grandiflorum against fatty liver in chronic ethanol feeding via the activation of AMP-dependent protein kinase. Food Chem. Toxicol 2009, 47, 2749–2754.
- Stevens, RL; Austen, KF. Recent advances in the cellular and molecular biology of mast cells. Immunol. Today 1989, 10, 381–386.
- Yamaguchi, M; Sayama, K; Yano, K; Lantz, CS; Noben-Trauth, N; Ra, C; Costa, JJ; Galli, SJ. IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: Synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol 1999, 162, 5455–5465.
- Murakami, M; Kudo, I. Diversity and regulatory functions of mammalian secretory phospholipase A2s. Adv. Immunol 2001, 77, 163–194.
- Kitamura, Y. Recent progress of mast cell research. Arerugi 2005, 54, 45–47.
- Muraguchi, A; Kishimoto, T; Miki, Y; Kuritani, T; Kaieda, T; Yoshizaki, K; Yamamura, Y. T cell-replacing factor (TRF)-induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J. Immunol 1981, 127, 412–416.
- Naka, T; Nishimoto, N; Kishimoto, T. The paradigm of IL-6: From basic science to medicine. Arthritis Res 2002, 3, S233–242.
- Kamimura, D; Ishihara, K; Hirano, T. IL-6 signal transduction and its physiological roles: The signal orchestration model. Rev. Physiol. Biochem. Pharmacol 2003, 149, 1–38.
- Smith, WL; Song, I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 2002, 68–69, 115–128.
- Crofford, LJ. COX-1 and COX-2 tissue expression: Implications and predictions. J. Rheumatol. Suppl 1997, 49, 15–19.
- Masferrer, JL; Seibert, K. Regulation of prostaglandin synthesis by glucocorticoids. Receptor 1994, 4, 25–30.
- Mitchell, JA; Akarasereenont, P; Thiemermann, C; Flower, RJ; Vane, JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci USA 1993, 90, 11693–11697.
- Seibert, K; Masferrer, JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994, 4, 17–23.
- Kay, AB. Overview of ‘allergy and allergic diseases: With a view to the future’. Br. Med. Bull 2000, 56, 843–864.
- Barnes, PJ; Adcock, I. Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharmacol. Sci 1993, 14, 436–441.
- Murakami, M; Matsumoto, R; Austen, KF; Arm, JP. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J. Biol. Chem 1994, 269, 22269–22275.
- Murakami, M; Austen, KF; Arm, JP. The immediate phase of c-kit ligand stimulation of mouse bone marrow-derived mast cells elicits rapid leukotriene C4 generation through posttranslational activation of cytosolic phospholipase A2 and 5-lipoxygenase. J. Exp. Med 1995, 182, 197–206.
- Moon, TC; Murakami, M; Kudo, I; Son, KH; Kim, HP; Kang, SS; Chang, HW. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflam. Res 1999, 48, 621–625.
- Lee, SH; Son, MJ; Ju, HK; Lin, CX; Moon, TC; Choi, HG; Son, JK; Chang, HW. Dual inhibition of cyclooxygenases-2 and 5-lipoxygenase by deoxypodophyllotoxin in mouse bone marrow-derived mast cells. Biol. Pharm. Bull 2004, 27, 786–788.
- Fiorucci, S; Meli, R; Bucci, M; Cirino, G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol 2001, 62, 1433–1438.
- Bochenek, G; Nizankowska, E; Gielicz, A; Swierczynska, M; Szczeklik, A. Plasma 9alpha, 11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 2004, 59, 459–464.
- Levi-Schaffer, F; Riesel, N; Soffer, D; Abramsky, O; Brenner, T. Mast cell activity in experimental allergic encephalomyelitis. Mol. Chem. Neuropathol 1991, 15, 173–184.
- Ha, YW; Na, YC; Seo, JJ; Kim, SN; Linhardt, RJ; Kim, YS. Qualitative and quantitative determination of ten major saponins in Platycodi Radix by high performance liquid chromatography with evaporative light scattering detection and mass spectrometry. J. Chromatogr. A 2006, 1135, 27–35.
|Table 1. Content of each compound.|
|8||3″-O-acetyl polygalacin D||2.3310|
|10||2″-O-acetyl polygalacin D||2.3579|
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).